Compare DARE & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DARE | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 35.8M |
| IPO Year | 2014 | 2018 |
| Metric | DARE | BTAI |
|---|---|---|
| Price | $2.08 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $10.00 | ★ $23.00 |
| AVG Volume (30 Days) | 147.6K | ★ 568.3K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,807,885.00 | N/A |
| Revenue This Year | $2,115.12 | $197.82 |
| Revenue Next Year | $122.62 | $910.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $1.01 |
| 52 Week High | $9.19 | $8.08 |
| Indicator | DARE | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 42.06 |
| Support Level | $1.95 | $1.05 |
| Resistance Level | $2.23 | $1.26 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 54.17 | 5.68 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.